These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 24480452)

  • 1. Efficacy of biologic agents in improving the Health Assessment Questionnaire (HAQ) score in established and early rheumatoid arthritis: a meta-analysis with indirect comparisons.
    Barra L; Ha A; Sun L; Fonseca C; Pope J
    Clin Exp Rheumatol; 2014; 32(3):333-41. PubMed ID: 24480452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of biologic therapy on functional status in patients with rheumatoid arthritis--a meta-analysis.
    Callhoff J; Weiß A; Zink A; Listing J
    Rheumatology (Oxford); 2013 Dec; 52(12):2127-35. PubMed ID: 23946435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Indirect treatment comparison of abatacept with methotrexate versus other biologic agents for active rheumatoid arthritis despite methotrexate therapy in the United kingdom.
    Guyot P; Taylor PC; Christensen R; Pericleous L; Drost P; Eijgelshoven I; Bergman G; Lebmeier M
    J Rheumatol; 2012 Jun; 39(6):1198-206. PubMed ID: 22505698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Challenge of Treating Early-Stage Rheumatoid Arthritis: The Contribution of Mixed Treatment Comparison to Choosing Appropriate Biologic Agents.
    Migliore A; Bizzi E; Petrella L; Bruzzese V; Cassol M; Integlia D
    BioDrugs; 2016 Apr; 30(2):105-15. PubMed ID: 26905069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biologic interventions for fatigue in rheumatoid arthritis.
    Almeida C; Choy EH; Hewlett S; Kirwan JR; Cramp F; Chalder T; Pollock J; Christensen R
    Cochrane Database Syst Rev; 2016 Jun; 2016(6):CD008334. PubMed ID: 27271314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Are All Biologics the Same? Optimal Treatment Strategies for Patients With Early Rheumatoid Arthritis: Systematic Review and Indirect Pairwise Meta-Analysis.
    Albert DA
    J Clin Rheumatol; 2015 Dec; 21(8):398-404. PubMed ID: 26226612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparing Effects of Biologic Agents in Treating Patients with Rheumatoid Arthritis: A Multiple Treatment Comparison Regression Analysis.
    Tvete IF; Natvig B; Gåsemyr J; Meland N; Røine M; Klemp M
    PLoS One; 2015; 10(9):e0137258. PubMed ID: 26356639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of adalimumab, etanercept, and tocilizumab as first-line treatments for moderate-to-severe rheumatoid arthritis.
    Soini EJ; Hallinen TA; Puolakka K; Vihervaara V; Kauppi MJ
    J Med Econ; 2012; 15(2):340-51. PubMed ID: 22168785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Defining the optimal biological monotherapy in rheumatoid arthritis: A systematic review and meta-analysis of randomised trials.
    Tarp S; Furst DE; Dossing A; Østergaard M; Lorenzen T; Hansen MS; Singh JA; Choy EH; Boers M; Suarez-Almazor ME; Kristensen LE; Bliddal H; Christensen R
    Semin Arthritis Rheum; 2017 Jun; 46(6):699-708. PubMed ID: 27769592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost per responder associated with biologic therapies for Crohn's disease, psoriasis, and rheumatoid arthritis.
    Liu Y; Wu EQ; Bensimon AG; Fan CP; Bao Y; Ganguli A; Yang M; Cifaldi M; Mulani P
    Adv Ther; 2012 Jul; 29(7):620-34. PubMed ID: 22843208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The durability of abatacept as a first and subsequent biologic and improvement in HAQ from a large multi-site real-world study.
    Pope JE; Rampakakis E; Sampalis J
    Semin Arthritis Rheum; 2015 Apr; 44(5):499-505. PubMed ID: 25440158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Similar effects of disease-modifying antirheumatic drugs, glucocorticoids, and biologic agents on radiographic progression in rheumatoid arthritis: meta-analysis of 70 randomized placebo-controlled or drug-controlled studies, including 112 comparisons.
    Graudal N; Jürgens G
    Arthritis Rheum; 2010 Oct; 62(10):2852-63. PubMed ID: 20560138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mixed treatment comparison of the treatment discontinuations of biologic disease-modifying antirheumatic drugs in adults with rheumatoid arthritis.
    Desai RJ; Hansen RA; Rao JK; Wilkins TM; Harden EA; Yuen A; Jonas DE; Roubey R; Jonas B; Gartlehner G; Lux L; Donahue KE
    Ann Pharmacother; 2012 Nov; 46(11):1491-505. PubMed ID: 23092868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative effectiveness of improvement in pain and physical function for baricitinib versus adalimumab, tocilizumab and tofacitinib monotherapies in rheumatoid arthritis patients who are naïve to treatment with biologic or conventional synthetic disease-modifying antirheumatic drugs: a matching-adjusted indirect comparison.
    Fautrel B; Zhu B; Taylor PC; van de Laar M; Emery P; De Leonardis F; Kannowski CL; Nicolay C; Kadziola Z; De La Torre I; Fleischmann R
    RMD Open; 2020 Apr; 6(1):. PubMed ID: 32371431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative Risk of Hospitalized Infection Associated With Biologic Agents in Rheumatoid Arthritis Patients Enrolled in Medicare.
    Yun H; Xie F; Delzell E; Levitan EB; Chen L; Lewis JD; Saag KG; Beukelman T; Winthrop KL; Baddley JW; Curtis JR
    Arthritis Rheumatol; 2016 Jan; 68(1):56-66. PubMed ID: 26315675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Characteristics of Rheumatoid Arthritis Patients Achieving Functional Remission after Six Months of Non-tumor Necrosis Factor Biological Disease-Modifying Antirheumatic Drugs (DMARDs) Treatment.
    Miwa Y; Saito M; Furuya H; Yanai R; Ikari Y; Hayashi T; Kasama T; Toyoshima Y; Inagaki K
    Intern Med; 2017 Sep; 56(17):2271-2275. PubMed ID: 28794381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Joint damage progression in patients with rheumatoid arthritis in clinical remission: do biologics perform better than synthetic antirheumatic drugs?
    Ciubotariu E; Gabay C; Finckh A;
    J Rheumatol; 2014 Aug; 41(8):1576-82. PubMed ID: 25028383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost per patient-year in response using a claims-based algorithm for the 2 years following biologic initiation in patients with rheumatoid arthritis.
    Bonafede M; Johnson BH; Princic N; Shah N; Harrison DJ
    J Med Econ; 2015 May; 18(5):376-89. PubMed ID: 25530318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: an investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial.
    Hørslev-Petersen K; Hetland ML; Junker P; Pødenphant J; Ellingsen T; Ahlquist P; Lindegaard H; Linauskas A; Schlemmer A; Dam MY; Hansen I; Horn HC; Ammitzbøll CG; Jørgensen A; Krintel SB; Raun J; Johansen JS; Østergaard M; Stengaard-Pedersen K;
    Ann Rheum Dis; 2014 Apr; 73(4):654-61. PubMed ID: 23434570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world anti-tumor necrosis factor treatment in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: cost-effectiveness based on number needed to treat to improve health assessment questionnaire.
    Barra L; Pope JE; Payne M
    J Rheumatol; 2009 Jul; 36(7):1421-8. PubMed ID: 19487267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.